Hired and Retired: Biotechs buildout at board level 27-May-2020 By Ben Hargreaves Numerous biotechs have brought onboard further experience at leadership level, with several seeking guidance on lead candidates.
WuXi AppTec launches closed process CAR-T platform 25-May-2020 By Ben Hargreaves The cell therapy platform will provide development, manufacturing and release services to companies working on CAR-T therapies.
Novartis’ gene therapy approved in Europe, talks ongoing on price 21-May-2020 By Ben Hargreaves The most expensive therapy in the world receives conditional approval in Europe.
Thermo Fisher set to build $180m viral vector site 18-May-2020 By Ben Hargreaves The site will be responsible for commercial manufacturing and will double the company’s viral vector capacity.
FDA refuses to file BMS treatment over manufacturing concerns 14-May-2020 By Ben Hargreaves US FDA knocks back BMS and bluebird’s application for ide-cel, demanding further details on CMC portion of BLA.
Biotech launches to create ‘rationally’ designed gene therapy 14-May-2020 By Ben Hargreaves Kriya Therapeutics launches publicly after raising $80.5m in financing, with three gene therapies in the pipeline.
BMS spends $200m to buy bluebird out of CAR-T payments 12-May-2020 By Ben Hargreaves With the partners’ CAR-T therapy under review by the FDA, BMS chooses to purchase bluebird’s royalty rights and take control of ex-US manufacturing.
Dyno launches with gene therapy partnership alongside Novartis 11-May-2020 By Ben Hargreaves The biotech emerges from stealth mode with two partnerships potentially worth in excess of $2bn.
AskBio buys BrainVectis for early-stage gene therapies 27-Apr-2020 By Ben Hargreaves AskBio acquires gene therapy biotech working on treatments for neurodegenerative disorders.
Mogrify and Sangamo in license agreement for ‘off-the-shelf’ CAR-Treg 23-Apr-2020 By Ben Hargreaves Sangamo plans to utilize Mogrify’s cell conversion technology to develop CAR-Treg cell therapies.
MilliporeSigma set to build $100m facility for viral and gene therapies 23-Apr-2020 By Ben Hargreaves The facility will be the company’s second facility in Carlsbad specifically for its BioReliance viral and gene therapy service.
How is the supply chain for immunotherapies impacted by COVID-19? 15-Apr-2020 By Ben Hargreaves COO of Dendreon explains how ‘every part’ of the supply chain for the company’s lead product has been affected by the novel coronavirus.
Takeda taps Evotec for gene therapy discovery 14-Apr-2020 By Ben Hargreaves Looking to expand its pipeline of gene therapies, Takeda announces a long-term research partnership with Evotec.
ElevateBio closes $170m Series B financing round 09-Apr-2020 By Ben Hargreaves The accelerator for cell and gene therapy startups reveals the closure of its second financing round and how the funds will be used.
Symbiosis doubles footprint of UK biologics site 09-Apr-2020 By Ben Hargreaves The CMO expands its Sterling site to add new office space, as well as expanding manufacturing space and supporting services.
